Literature DB >> 11114726

Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation.

A Pierce1, E Spooncer, S Wooley, C Dive, J M Francis, J Miyan, P J Owen-Lynch, T M Dexter, A D Whetton.   

Abstract

Chronic myeloid leukaemia is a haemopoietic stem cell disorder, the hallmark of which is the expression of the Bcr-Abl Protein Tyrosine Kinase (PTK). We have previously reported that activation of a temperature sensitive Bcr-Abl PTK in the multipotent haemopoietic cell line FDCP-Mix for short periods resulted in subtle changes including, a transient suppression of apoptosis and no inhibition of differentiation. In contrast, activation of the Bcr-Abl PTK for 12 weeks results in cells that display a delay in differentiation at the early granulocyte stage. Flow cytometric analysis also indicates that the expression of cell surface differentiation markers and nuclear morphology are uncoupled. Furthermore, a significant number of the mature neutrophils display abnormal morphological features. Prolonged exposure to Bcr-Abl PTK results in interleukin-3 independent growth and decreased p53 protein levels. FDCP-Mix cells expressing a dominant negative p53 and p53null FDCP-Mix cells demonstrate that the reduction in p53 is causally related to the delay in development. Returning the cells to the restrictive temperature restores the p53 protein levels, the growth factor dependence and largely relieves the effects on development. We conclude that prolonged Bcr-Abl PTK activity within multipotent cells results in a reduction of p53 that drives a delayed and abnormal differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114726     DOI: 10.1038/sj.onc.1203940

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

2.  OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Authors:  Jane R Engler; Andrew C W Zannettino; Charles G Bailey; John E J Rasko; Timothy P Hughes; Deborah L White
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

3.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Authors:  Ji Suk Chang; Ramasamy Santhanam; Rossana Trotta; Paolo Neviani; Anna M Eiring; Edward Briercheck; Mattia Ronchetti; Denis C Roy; Bruno Calabretta; Michael A Caligiuri; Danilo Perrotti
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

Review 4.  Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells.

Authors:  Takumi Era
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

5.  Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.

Authors:  Kaushiki Mukherjee; Xiaojin Sha; Andrew Magimaidas; Silvia Maifrede; Tomasz Skorski; Ravi Bhatia; Barbara Hoffman; Dan A Liebermann
Journal:  Oncotarget       Date:  2017-02-14

6.  Computational Identification of BCR-ABL Oncogenic Signaling as a Candidate Target of Withaferin A and Withanone.

Authors:  Vidhi Malik; Navaneethan Radhakrishnan; Sunil C Kaul; Renu Wadhwa; Durai Sundar
Journal:  Biomolecules       Date:  2022-01-26

7.  Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia.

Authors:  Silvia Maifrede; Andrew Magimaidas; Xiaojin Sha; Kaushiki Mukherjee; Dan A Liebermann; Barbara Hoffman
Journal:  Oncotarget       Date:  2017-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.